Tue, Jan 27, 2015, 8:40 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

  • le54roid le54roid Jan 4, 2013 8:45 AM Flag

    Too funny. We get an upgrade from Brean Murray

    and a downgrade from Cantor. I guess it's a punt for today

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Brean Murray initiated coverage with a "Buy". Anybody know what their PT is?

    • Unfortunately it looks like CF is the one in the press. Here is what they say:

      The firm comments, "After attending a Hepatitis C lecture and speaking with physicians at the New York Society for Gastrointestinal Endoscopy on December 19 we are lowering our estimates on Promacta in the Hepatitis C (HCV) indication from $337M to $67.5M in 2017. Our reasons are as follows: (1) Physician awareness of Promacta in HCV is minimal a month after its approval and reimbursement is believed to be non-existent; (2) doctors indicated that low platelet levels are not a key reason for keeping very sick HCV patients off interferon treatments; (3) presenters indicated that effective non-interferon treatments are expected to be introduced in the next 2-3 years (which does not allow time for significant Promacta ramp, in our view); and (4) weekly prescription trends are not showing any significant pick-up since approval."

      There is probably some truth in what they're saying but hopefully GSK is working on the awareness issue. Obviously everyone already knows about the non-interferon treatments. Also, the drug is used so much off label that I think it's very difficult to predict 2017 revenues. I will be reloading today if we dip below $20

58.56+2.00(+3.54%)Jan 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.